Gosset Ownership
Public
Employees
~2100
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Alnylam Pharmaceuticals General Information
Alnylam is the global leader in RNA interference therapeutics with five approved medicines as of 2025. Its drugs have demonstrated significant efficacy for rare genetic diseases such as hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and cardiovascular disease. The company continues to expand its clinical pipeline into new indications and organ systems beyond the liver
Contact Information
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
patisiran
CommercialKey Partnerships
Novartis (Leqvio), Regulus Therapeutics (co-founded with Ionis), past partnerships with Medtronic, Biogen Idec/Biogen Inc., Hoffmann-La Roche/Ionis Pharmaceuticals
Alnylam Pharmaceuticals Funding
No funding data available
To view Alnylam Pharmaceuticals's complete valuation and funding history, request access »
Alnylam Pharmaceuticals Financial Metrics
Market Cap
$41920.8M
Total Revenue
$1097.0M
Enterprise Value
$40290.7M